More Co-Sponsors for Medicare "Any Willing Pharmacy" Legislation
The lead sponsors of
U.S. Reps. Morgan Griffith (R-Va.) and Peter Welch (D-Vt.) recently sent a “Dear Colleague” letter out to their fellow House members seeking their support for the bipartisan proposal.
H.R. 4577 has 22 co-sponsors at the moment. Among the supporters are the chairmen of two major committees.
Rep. Bob Goodlatte (R-Va.) leads the House Judiciary Committee. In 2012 he scheduled and presided over a
Rep. Bill Shuster (R-Pa.) heads the House Transportation & Infrastructure Committee. He also represents the Ninth Congressional District, in which his constituents rely on independent community pharmacies like
“Medicare Part D preferred pharmacy network plans were designed to make prescription drugs more affordable for beneficiaries,” wrote Griffith and Welch. “However, these plans have also created confusion for seniors and put community pharmacies at a competitive disadvantage. Some seniors, especially in rural areas, have reported having to travel upwards of 20 miles in order to get their medications from a preferred pharmacy network because their local community pharmacy was not given the opportunity to participate in such a network.
“[The Centers for Medicare & Medicaid Services or CMS] had proposed to address this problem by requiring Part D plans to include “any willing pharmacy” that would accept the plan’s pricing and terms in their preferred network, but that provision of the draft rule was later rescinded. We support CMS’s policy proposal, and in order to make this the law of the land, we recently introduced H.R. 4577, the Ensuring Seniors Access to Local Pharmacies Act, to address this problem in a more tailored way. Our bill allows any willing pharmacy located within a HRSA-designated medically underserved or health professional shortage area to participate in Part D preferred networks.”
Learn more at
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025